The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
VAXCYTE INC COM 92243G108 26,842 1,111,485 SH   DFND 1 0 1,111,485 0
BOLT BIOTHERAPEUTICS INC COM 097702104 5,183 1,891,467 SH   DFND 1 0 1,891,467 0
INOZYME PHARMA INC COM 45790W108 6,508 1,591,154 SH   DFND 1 0 1,591,154 0
RALLYBIO CORP COM 75120L100 15,854 2,271,311 SH   DFND 1 0 2,271,311 0
KARUNA THERAPEUTICS INC COM 48576A100 108,115 852,708 SH   DFND 1 0 852,708 0
ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 10,960 569,041 SH   DFND 1 0 569,041 0
ALIGOS THERAPEUTICS INC COM 01626L105 1,885 876,548 SH   DFND 1 0 876,548 0
AKOUOS INC COM 00973J101 8,522 1,794,088 SH   DFND 1 0 1,794,088 0
FUSION PHARMACEUTICALS INC COM 36118A100 12,419 1,598,377 SH   DFND 1 0 1,598,377 0
EXSCIENTIA PLC ADS 30223G102 11,121 772,285 SH   DFND 1 0 772,285 0
VIGIL NEUROSCIENCE INC COM 92673K108 3,941 560,595 SH   DFND 1 0 560,595 0